Studies examining body composition changes during GLP-1 therapy, including the STEP trials (semaglutide) and SURMOUNT-1 (tirzepatide), have demonstrated that approximately 2540% of total weight lost may come from lean body mass, including skeletal muscle, rather than exclusively from fat mass
Whether addressing the gender health gap, improving access to diagnostics or accelerating the uptake of new technologies, international collaboration will be essential
And whether you're dealing with semaglutide constipation, nausea, fatigue, or headaches, the team at Injx Bar is committed to helping you find effective solutions and improve your overall well-being
Psychoneuroendocrinology 63
Patients with type 2 diabetes should be monitored closely, especially for changes in vision or worsening eye disease